Cytokinetics (NASDAQ: CYTK) prices $760.2M common stock sale at $71
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Cytokinetics, Incorporated entered into an underwriting agreement for a public offering of 9,859,155 shares of its common stock at a public offering price of $71.00 per share.
The underwriters received a 30-day option to buy up to an additional 1,478,873 shares, which they fully exercised on May 7, 2026. After underwriting discounts, commissions and estimated expenses, net proceeds to Cytokinetics from the offering are approximately $760.2 million, providing substantial new capital to the company.
Positive
- None.
Negative
- None.
Insights
Cytokinetics raises about $760M via sizable follow-on stock sale.
Cytokinetics completed a large underwritten public stock offering, selling 9,859,155 shares at $71.00 each, with underwriters fully exercising an option for 1,478,873 additional shares. Net proceeds of approximately $760.2 million significantly increase the company’s cash resources.
This transaction brings in primary equity capital but also expands the share count, which can dilute existing holders. The deal was executed off an automatic shelf registration on Form S-3, using a final prospectus supplement dated May 6, 2026, and involves major underwriters such as Morgan Stanley, Goldman Sachs, J.P. Morgan and Jefferies.
The balance between added financial flexibility and dilution depends on how effectively the company deploys the new funds. Future disclosures in periodic reports and investor materials may provide more detail on how this capital supports operations, development programs or other corporate purposes.
8-K Event Classification
2 items: 8.01, 9.01
2 items
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Primary shares offered: 9,859,155 shares
Underwriters’ option shares: 1,478,873 shares
Offering price: $71.00 per share
+3 more
6 metrics
Primary shares offered
9,859,155 shares
Public offering of common stock
Underwriters’ option shares
1,478,873 shares
30-day option, exercised in full May 7, 2026
Offering price
$71.00 per share
Public offering price for common stock
Net proceeds
$760.2 million
After discounts, commissions and estimated expenses
Shelf registration form
Form S-3, File No. 333-285376
Automatic shelf used for the offering
Prospectus supplement date
May 6, 2026
Final prospectus supplement describing terms
Key Terms
Underwriting Agreement, public offering, automatic shelf registration statement, prospectus supplement, +1 more
5 terms
Underwriting Agreement financial
"entered into an underwriting agreement (the “Underwriting Agreement”) with Morgan Stanley & Co. LLC"
An underwriting agreement is a contract where a company selling new stocks or bonds hires financial firms to buy those securities and resell them to investors. It matters because the agreement sets the offering price, number of securities, fees and which party bears the risk if sales fall short—think of it as a promise that the sale will happen and a roadmap investors can use to understand how the new securities reach the market.
public offering financial
"relating to the public offering, issuance and sale (the “Offering”) of 9,859,155 shares"
A public offering is when a company sells shares to the general public through the stock market, either by issuing new shares to raise cash or by letting existing owners sell their stakes. Think of it like a business opening its doors to many new owners at once: it can bring in money for growth but also increases the number of shares available, which can change the stock price and dilute existing ownership — key factors investors watch closely.
automatic shelf registration statement regulatory
"The Offering was made pursuant to an automatic shelf registration statement on Form S-3"
An automatic shelf registration statement is a pre-approved filing that companies submit to securities regulators, allowing them to sell new shares or bonds quickly and efficiently when needed. It acts like a standing permit, enabling the company to raise money without going through a lengthy approval process each time, which can be helpful for responding promptly to market opportunities or needs. For investors, it provides transparency about the company's ability to raise funds and signals planning flexibility.
prospectus supplement regulatory
"A final prospectus supplement dated May 6, 2026 relating to and describing the terms of the Offering"
A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.
indemnification obligations financial
"The Underwriting Agreement contains customary representations, warranties and agreements by the Company, customary conditions to closing, indemnification obligations"
A company's indemnification obligations are promises it has made to cover certain losses, legal costs, or damages that another party might suffer because of the company’s actions or events tied to a deal. Think of it like a guarantee or built-in insurance: if something goes wrong, the company must step in and pay. For investors this matters because these potential payouts create contingent liabilities that can reduce cash, raise legal exposure, and affect a company’s value and risk profile.
FAQ
What did Cytokinetics (CYTK) announce in this 8-K filing?
Cytokinetics announced a public underwritten offering of common stock. The company sold 9,859,155 shares at $71.00 per share and granted underwriters a 30-day option for 1,478,873 additional shares, which was fully exercised, generating approximately $760.2 million in net proceeds.
How much capital did Cytokinetics (CYTK) raise in the stock offering?
Cytokinetics raised approximately $760.2 million in net proceeds from the offering. This figure includes the shares sold under the fully exercised underwriters’ option and is calculated after deducting underwriting discounts, commissions, and estimated offering expenses paid by the company.
What were the terms of Cytokinetics’ (CYTK) common stock offering?
Cytokinetics sold 9,859,155 shares of common stock at a public offering price of $71.00 per share. Underwriters also received a 30-day option to purchase up to 1,478,873 additional shares at the same price, and they exercised this option in full on May 7, 2026.
Which banks underwrote the Cytokinetics (CYTK) equity offering?
The equity offering was underwritten by a syndicate led by Morgan Stanley & Co. LLC, Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC, and Jefferies LLC. These firms acted as representatives of the several underwriters named in the underwriting agreement dated May 6, 2026.
Under what registration did Cytokinetics (CYTK) conduct this offering?
The offering was conducted under an automatic shelf registration statement on Form S-3, File No. 333-285376. This registration was filed with the U.S. Securities and Exchange Commission on February 27, 2025 and became effective automatically upon filing, enabling the company to issue the shares.
What legal opinions were filed with Cytokinetics’ (CYTK) 8-K for this offering?
Cytokinetics filed an opinion from Gibson, Dunn & Crutcher LLP as Exhibit 5.1, addressing the validity of the common stock issued. A related consent from the same firm was included as Exhibit 23.1, supporting the legal framework for the registered shares in the public offering.